Innovation Insights: AI in antibody/biologics discovery

Innovation Insights: AI in antibody/biologics discovery

Summary

The application of AI and ML technologies for biologics screening is a high-impact innovation with strong commercial activity, including acquisitions and partnerships among key players. Patenting activity in this area has been consistently growing since 2018, with a significant increase in 2023. The rapid growth is attributed to the rise in AI technology, with a technology cycle time of 1.1 years. China and the US are the leading geographies in this field, with over 40% of all patents filed by universities. Among the 40+ companies identified in this space, China-based tech companies Baidu and Ping An are in the top-10, along with Merck & Co, BioNTech, Alphabet, NEC, Accenture, IBM, Microsoft, Evaxion, iBio, and Codexis.

The application of new AI & ML technologies for biologics screening in drug discovery has been identified as a high-impact innovation with strong commercial activity. Patenting activity has been steadily increasing since 2018, with a notable doubling in 2023, driven by the rapid growth of AI technology. The technology cycle time for AI-based biologics screening is 1.1 years, indicating quick development cycles. China and the US are leading geographies in this field, with universities filing over 40% of all patents. Competitive intelligence reveals top players such as Baidu, Ping An, Merck & Co, and BioNTech, with tech companies like Alphabet, NEC, and IBM leading the way. Evaxion, iBio, and Codexis are prominent in the healthtech sector.

How is our ‘State of Innovation intelligence 2024’ report unique from other reports in the market?

360° Market View: It consolidates patents, drugs, clinical trials, and deals data into one comprehensive resource, unlike many reports that focus on a single data type.

Targeted AI Insights: Specifically tailored to the intersection of AI and biological drug discovery, it delivers focused insights on how AI is transforming the drug discovery process.

Competitive Landscape Analysis: Offers deep competitive intelligence by tracking both established players and emerging startups, including strategic partnerships and investment trends.

Actionable Intelligence: Equips stakeholders with actionable insights to refine R&D strategies, identify licensing opportunities, and navigate regulatory challenges.

Advanced Analytics: Utilizes state-of-the-art data analytics and visualization techniques to turn complex data into clear, strategic guidance.

We recommend this valuable source of information to anyone involved in -

Drug Development and Pharma/Biotech Companies - Value chain
Pharmaceutical Industry Suppliers and Distributors
Pharma/Drug Manufacturing Companies - Leaders and Startups
Business Development and Market Intelligence
Investment Analysts and Portfolio Managers
Professional Services - Investment Banks, PE/VC Firms
M&A/Investment, Management Consultants, and Consulting Firms

Key Highlights

• AI for biologics screening is a high-impact innovation with strong commercial activity, including asset-driven acquisitions and co-development partnerships.
• Patenting activity has been steadily growing since 2018, doubling in 2023, driven by the rapid growth of AI technology.
• Technology cycle time for AI-based biologics screening is 1.1 years, indicating quick development cycles.
• China and the US are leading geographies in this field, with universities filing over 40% of all patents.
• Top players include Baidu, Ping An, Merck & Co, and BioNTech, with tech companies like Alphabet, NEC, and IBM leading the way in competitive intelligence.

• Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.
• Key player: This represents a sample list of key players in each use case highlighted in the report.
• Startups: This represents a sample list of emerging starups in each use case highlighted in the report.
• University: This represents a sample list of leading universities in each use case highlighted in the report.

• Comprehensive Market Overview - Gain a holistic understanding of the growing role of AI and ML technologies in biologics screening, including insights into patents, clinical trials, and strategic industry deals.
• Track Cutting-Edge Innovations - Stay at the forefront by exploring how AI is revolutionizing biologics screening, with an emphasis on breakthrough research, emerging technologies, and industry developments.
• Competitive Landscape Analysis - Identify leading players in AI-driven biologics screening, such as Baidu, Merck, BioNTech, and more, to help position your company for success in this rapidly advancing sector.
• Optimize R&D Strategy - Leverage insights to streamline your research and development processes, refine biologics screening pipelines, and accelerate time-to-market for innovative treatments.
• Navigate IP and Regulatory Challenges - Understand patent trends and potential regulatory hurdles to mitigate risks and identify valuable licensing and intellectual property opportunities.
• Investment & Partnership Insights - Discover key M&A activity, partnership trends, and investment opportunities in the AI-driven biologics space to guide future growth and strategic collaborations.